RICHLAND, Wash.--(BUSINESS WIRE)--Sept. 6, 2006--IsoRay, Inc. (“IsoRay”) (OTCBB:ISRY), a medical isotope company focusing on brachytherapy solutions for prostate and other malignant tissue cancers through use of its proprietary Cesium-131 radioisotope, announced its preliminary financial results for the fiscal year ended June 30, 2006, and anticipated first quarter 2007 ending September 30, 2006. The financial results reported today do not take into account any adjustments that may be required in connection with the completion of the Company’s audit and review process and should be considered preliminary until IsoRay files its Form 10-KSB for the fiscal year ended June 30, 2006, and Form 10-QSB for the quarter ended September 30, 2006.
